Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. It disproportionately affects BRCA mutation carriers and young women, especially African American (AA) women. Chemoresistant TNBC is a heterogeneous and molecularly unstable disease that challenges our ability to apply personalized therapies. With the approval of immune checkpoint blockade (ICB) for TNBC, the addition of pembrolizumab to systemic chemotherapy has become standard of care (SOC) in neoadjuvant systemic therapy (NST) for high-risk early-stage TNBC. Pembrolizumab plus chemotherapy significantly increased the pathologic complete response (pCR) and improved event-free survival in TNBC. However, clinical uncertainties remain because similarly treated TNBC partial responders with comparable tumor responses to neoadjuvant therapy often experience disparate clinical outcomes. Current methods fall short in accurately predicting which high-risk patients will develop chemo-resistance and tumor relapse. Therefore, novel treatment strategies and innovative new research initiatives are needed. We propose that the EGFR-K-RAS-SIAH pathway activation is a major tumor driver in chemoresistant TNBC. Persistent high expression of SIAH in residual tumors following NACT/NST reflects that the EGFR/K-RAS pathway remains activated (ON), indicating an ineffective response to treatment. These chemoresistant tumor clones persist in expressing SIAH (SIAH^High/ON) and are linked to early tumor relapse and poorer prognosis. Conversely, the loss of SIAH expression (SIAH^Low/OFF) in residual tumors post-NACT/NST reflects EGFR/K-RAS pathway inactivation (OFF), indicating effective therapy and chemo-sensitive tumor cells. SIAH^Low/OFF signal is linked to tumor remission and better prognosis post-NACT/NST. Therefore, SIAH is well-positioned to become a novel tumor-specific, therapy-responsive, and prognostic biomarker. Potentially, this new biomarker (SIAH^High/ON) could be used to quantify therapy response, predict chemo-resistance, and identify those patients at the highest risk for tumor relapse and poor survival in TNBC.

Keywords

Triple-negative breast cancer (TNBC) / chemo-resistance / seven in absentia (SINA) and human homologs of SINA (SIAH) E3 ligase / ubiquitin-mediated proteolysis / EGFR/K-RAS/SIAH pathway activation in TNBC / neoadjuvant chemotherapy prognosis / patient risk stratification / detection of chemo-resistance / precision quantification of therapy efficacy / and treatment optimization

References

[1] Mahtani R,Kalinsky K.Breast Cancer Therapy Expert Group (BCTEG)Advances in therapeutic approaches for triple-negative breast cancer.Clin Breast Cancer2021;21:383-90

[2] Howard FM.Epidemiology of triple-negative breast cancer: a review.Cancer J2021;27:8-16

[3] Gupta GK,Lee D.Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies.Cancers (Basel)2020;12:2392 PMCID:PMC7565566

[4] Luo SP,Chen H.Validation of the prognostic significance of the prognostic stage group according to the eighth edition of american cancer joint committee on cancer staging system in triple-negative breast cancer: an analysis from surveillance, epidemiology, and end results 18 database.J Surg Res2020;247:211-9

[5] Foulkes WD,Reis-Filho JS.Triple-negative breast cancer.N Engl J Med2010;363:1938-48

[6] Giaquinto AN,Tossas KY,Jemal A.Cancer statistics for African American/black people 2022.CA Cancer J Clin2022;72:202-29

[7] Nwagu GC,Swahn M,Aneja R.Prevalence and mortality of triple-negative breast cancer in west africa: biologic and sociocultural factors.JCO Glob Oncol2021;7:1129-40 PMCID:PMC8457872

[8] DeSantis CE,Goding Sauer A,Siegel RL.Cancer statistics for African Americans, 2019.CA Cancer J Clin2019;69:211-33

[9] Newman LA,Chen Y.Hereditary susceptibility for triple negative breast cancer associated with western sub-saharan african ancestry: results from an international surgical breast cancer collaborative.Ann Surg2019;270:484-92

[10] Bianchini G,Mayer IA,Gianni L.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Nat Rev Clin Oncol2016;13:674-90 PMCID:PMC5461122

[11] Boyle P.Triple-negative breast cancer: epidemiological considerations and recommendations.Ann Oncol2012;23 Suppl 6:vi7-12

[12] Pal SK,Pegram M.Triple negative breast cancer: unmet medical needs.Breast Cancer Res Treat2011;125:627-36 PMCID:PMC3244802

[13] Carey L,Viale G,Gianni L.Triple-negative breast cancer: disease entity or title of convenience?.Nat Rev Clin Oncol2010;7:683-92

[14] Scott LC,Kuo TM.Update on triple-negative breast cancer disparities for the United States: a population-based study from the United States Cancer Statistics database, 2010 through 2014.Cancer2019;125:3412-7 PMCID:PMC6744285

[15] Thomas A,Pinkerton E.Incidence and survival among young women with stage I-III breast cancer: SEER 2000-2015.JNCI Cancer Spectr2019;3:pkz040 PMCID:PMC6668585

[16] Howlader N,Kurian AW.Differences in breast cancer survival by molecular subtypes in the united states.Cancer Epidemiol Biomarkers Prev2018;27:619-26

[17] Newman LA.Health disparities and triple-negative breast cancer in african american women: a review.JAMA Surg2017;152:485-93

[18] Zardavas D,Swanton C.Clinical management of breast cancer heterogeneity.Nat Rev Clin Oncol2015;12:381-94

[19] Schroeder MC,Geyer CE Jr,Thomas A.Early and locally advanced metaplastic breast cancer: presentation and survival by receptor status in surveillance, epidemiology, and end results (SEER) 2010-2014.Oncologist2018;23:481-8 PMCID:PMC5896714

[20] Andreopoulou E,Sparano JA.Therapies for triple negative breast cancer.Expert Opin Pharmacother2015;16:983-98 PMCID:PMC5995333

[21] Kennedy WR,Gabani P.Predictors of distant metastases in triple-negative breast cancer without pathologic complete response after neoadjuvant chemotherapy.J Natl Compr Canc Netw2020;18:288-96

[22] Savard MF,Hunt KK.Redrawing the lines: the next generation of treatment in metastatic breast cancer.Am Soc Clin Oncol Educ Book2019;39:e8-e21

[23] Gabani P,Srivastava AJ.Predictors of locoregional recurrence after failure to achieve pathologic complete response to neoadjuvant chemotherapy in triple-negative breast cancer.J Natl Compr Canc Netw2019;17:348-56

[24] Gradishar WJ,Abraham J.NCCN Guidelines Insights: Breast Cancer, Version 4.2021.J Natl Compr Canc Netw2021;19:484-93

[25] Nedeljković M.Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge.Cells2019;8:957 PMCID:PMC6770896

[26] Ciriello G,Beck AH.TCGA Research NetworkComprehensive molecular portraits of invasive lobular breast cancer.Cell2015;163:506-19 PMCID:PMC4603750

[27] Isakoff SJ,He L.TBCRC009: A multicenter phase ii clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer.J Clin Oncol2015;33:1902-9 PMCID:PMC4451173

[28] Genome Atlas Network. Comprehensive molecular portraits of human breast tumours.Nature2012;490:61-70 PMCID:PMC3465532

[29] Andreopoulou E,McDaid HM.Therapeutic advances and new directions for triple-negative breast cancer.Breast Care (Basel)2017;12:21-8 PMCID:PMC5465752

[30] Savas P.Expanding the role for immunotherapy in triple-negative breast cancer.Cancer Cell2020;37:623-4

[31] Killock D.Chemotherapy as a TONIC to invigorate PD-1 inhibition in TNBC.Nat Rev Clin Oncol2019;16:464

[32] Sidaway P.Setting dictates efficacy of pembrolizumab in TNBC.Nat Rev Clin Oncol2019;16:66

[33] Schmid P,Adams S.Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2020;21:44-59

[34] Adams S,Barrios CH.Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.Ann Oncol2020;31:582-9

[35] Schmid P,Pusztai L.KEYNOTE-522 InvestigatorsPembrolizumab for early triple-negative breast cancer.N Engl J Med2020;382:810-21

[36] Nanda R,Yau C.Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.JAMA Oncol2020;6:676-84 PMCID:PMC7058271

[37] Schmid P,Dent R.KEYNOTE-522 InvestigatorsEvent-free survival with pembrolizumab in early triple-negative breast cancer.N Engl J Med2022;386:556-67

[38] Cortes J,Rugo HS.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.The Lancet2020;396:1817-28

[39] Kennedy LB.A review of cancer immunotherapy toxicity.CA Cancer J Clin2020;70:86-104

[40] Symmans WF,Gould R.Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype.J Clin Oncol2017;35:1049-60 PMCID:PMC5455352

[41] Symmans WF,Hatzis C.Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.J Clin Oncol2007;25:4414-22

[42] Weiss A,Ballman KV.Factors associated with nodal pathologic complete response among breast cancer patients treated with neoadjuvant chemotherapy: results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).Ann Surg Oncol2021;28:5960-71 PMCID:PMC8532250

[43] LeVasseur N,Gondara L.Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis.J Cancer Res Clin Oncol2020;146:529-36

[44] Cortazar P,Untch M.Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.The Lancet2014;384:164-72

[45] Wu K,Liu Y,Yang Z.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.World J Surg Oncol2014;12:95 PMCID:PMC4011773

[46] Biswas T,Prasad S,Walker PR.The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer.Oncotarget2017;8:112712-9 PMCID:PMC5762543

[47] Esserman LJ,DeMichele A.Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.J Clin Oncol2012;30:3242-9 PMCID:PMC3434983

[48] Symmans WF,Chen YY.Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial.JAMA Oncol2021;7:1654-63 PMCID:PMC8446908

[49] Echeverria GV,Seth S.Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state.Sci Transl Med2019;11:eaav0936 PMCID:PMC6541393

[50] Carbognin L,Vicentini C.Neoadjuvant strategies for triple negative breast cancer: ‘state-of-the-art’ and future perspectives.Anticancer Agents Med Chem2015;15:15-25

[51] Mougalian SS,Killelea BK.Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.Cancer2015;121:2544-52

[52] Masuda N,Ohtani S.Adjuvant capecitabine for breast cancer after preoperative chemotherapy.N Engl J Med2017;376:2147-59

[53] Gradishar WJ,Abraham J.Breast Cancer, Version 3.2020, NCCN clinical practice guidelines in Oncology.J Natl Compr Canc Netw2020;18:452-78

[54] Li Y,Mao F.Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.Breast Cancer Res Treat2020;179:533-42

[55] DeSantis CE,Gaudet MM.Breast cancer statistics, 2019.CA Cancer J Clin2019;69:438-51

[56] Carey LA.I-SPY 2--toward more rapid progress in breast cancer treatment.N Engl J Med2016;375:83-4

[57] Zong Y.Research advances and new challenges in overcoming triple-negative breast cancer.Cancer Drug Resist2021;4:517-42 PMCID:PMC8654168

[58] O’Reilly D,Kelly CM.Overview of recent advances in metastatic triple negative breast cancer.World J Clin Oncol2021;12:164-82 PMCID:PMC7968109

[59] Konner M.Progress in the treatment of breast cancer.N Engl J Med2020;382:e4

[60] Waks AG.Breast cancer treatment: a review.JAMA2019;321:288-300

[61] Cao J,Wang B,Zhou F.Chemoresistance and metastasis in breast cancer molecular mechanisms and novel clinical strategies.Front Oncol2021;11:658552 PMCID:PMC8281885

[62] Marra A.Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy.Cancer J2021;27:41-9

[63] Kumar S,Singh S.Dll1⁺ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway.Nat Commun2021;12:432 PMCID:PMC7813834

[64] Wu SZ,Wang C.Stromal cell diversity associated with immune evasion in human triple-negative breast cancer.EMBO J2020;39:e104063 PMCID:PMC7527929

[65] Cazet AS,Elsworth BL.Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.Nat Commun2018;9:2897 PMCID:PMC6057940

[66] Kabraji S,Huang Y.AKT1^low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer.Breast Cancer Res2017;19:88 PMCID:PMC5540189

[67] Zhang Y,Mo H.Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer.Cancer Cell2021;39:1578-1593.e8

[68] Chakrabarty A,Bhattacharya R.Senescence-induced chemoresistance in triple negative breast cancer and evolution-based treatment strategies.Front Oncol2021;11:674354 PMCID:PMC8264500

[69] Kvokačková B,Jolly MK.Phenotypic heterogeneity of triple-negative breast cancer mediated by epithelial-mesenchymal plasticity.Cancers (Basel)2021;13:2188 PMCID:PMC8125677

[70] Marra A,Viale G,Curigliano G.Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies.NPJ Breast Cancer2020;6:54 PMCID:PMC7568552

[71] Kim C,Sei E.Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing.Cell2018;173:879-893.e13 PMCID:PMC6132060

[72] Gupta G,Guye ML.Unmet clinical need: developing prognostic biomarkers and precision medicine to forecast early tumor relapse, detect chemo-resistance and improve overall survival in high-risk breast cancer.Ann Breast Cancer Ther2020;4:48-57 PMCID:PMC7295150

[73] Dias Carvalho P,Cardoso AP.KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment.Cancer Res2018;78:7-14

[74] Loi S,Beavis PA.RAS/MAPK Activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors.Clin Cancer Res2016;22:1499-509 PMCID:PMC4794351

[75] Jiang W,Zhang C,Yang L.Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer.Oncol Lett2020;19:1842-8 PMCID:PMC7038935

[76] van Reesema LLS,Winston JS.SIAH and EGFR, two RAS pathway biomarkers, are highly prognostic in locally advanced and metastatic breast cancer.EBioMedicine2016;11:183-98 PMCID:PMC5049993

[77] Van Sciver RE,Isbell AJ, et al.Blocking SIAH proteolysis, an important K-RAS vulnerability, to control and eradicate K-RAS-driven metastatic cancer. In: Azmi AS, editor Conquering RAS : from biology to cancer therapy. Amsterdam ; Boston: Elsevier/AP, Academic Press is an imprint of Elsevier. 2016.

[78] Wright KL,Liu JC.Ras signaling is a key determinant for metastatic dissemination and poor survival of luminal breast cancer patients.Cancer Res2015;75:4960-72

[79] Simon MA,Fortini ME,Mardon G.Signal transduction pathway initiated by activation of the sevenless tyrosine kinase receptor.Cold Spring Harb Symp Quant Biol1992;57:375-80

[80] Zipursky SL.Determination of neuronal cell fate: lessons from the R7 neuron of Drosophila.Annu Rev Neurosci1994;17:373-97

[81] Zipursky SL.Determination of neuronal cell fate: lessons from the R7 neuron of Drosophila.Annu Rev Neurosci1994;17:373-97

[82] Schmidt RL,Ahmed AU.Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue.Cancer Res2007;67:11798-810

[83] Ahmed AU,Park CH.Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth.J Natl Cancer Inst2008;100:1606-29 PMCID:PMC2720765

[84] Pepper IJ,Tang AH.Phylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa.BMC Evol Biol2017;17:182 PMCID:PMC5547486

[85] Van Sciver RE,Lee CD.A new strategy to control and eradicate “undruggable” oncogenic k-ras-driven pancreatic cancer: molecular insights and core principles learned from developmental and evolutionary biology.Cancers (Basel)2018;10:142 PMCID:PMC5977115

[86] Tang AH,Kwan E.PHYL acts to down-regulate TTK88, a transcriptional repressor of neuronal cell fates, by a SINA-dependent mechanism.Cell1997;90:459-67

[87] Hu G,Glover T,Look AT.Characterization of human homologs of the Drosophila seven in absentia (sina) gene.Genomics1997;46:103-11

[88] Carthew RW.seven in absentia, a gene required for specification of R7 cell fate in the Drosophila eye.Cell1990;63:561-77

[89] Siewertsz van Reesema LL,Zheleva V et al.RAS pathway biomarkers for breast cancer prognosis.Clin Lab Int2016;40:18-23 PMCID:PMC5455995